A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)

StatusRecruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 4 more changesShow less
    • Trial sites expanded: 0 → 8 locations
    • Start date changed from estimate of Sep 3, 2026 to Sep 24, 2026
    • Eligibility criteria expanded, about 32 words
    • Secondary endpoints: details revised at 3 of 19 entries
  2. Interventions modified
    • Eligibility criteria shortened, about 31 words
    • Secondary endpoints revised (19)
    • Study title expanded, about 1 word
    v3
  3. Collaborator revisedv2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to see how well mocertatug rezetecan (Mo-Rez) in combination with physician's choice of immunotherapy (dostarlimab or pembrolizumab) works as maintenance therapy in participants with advanced or recurrent endometrial cancer (EC) compared with the physician's choice of immunotherapy (dostarlimab or pembrolizumab) alone, which represents the current standard of care. The study will also assess whether the drug combination is safe and tolerated well by participants compared to standard of care and will help us better understand its impact on Health-Related Quality of Life of participants.
Trial Details
NCT Number NCT07684599
Lead Sponsor GlaxoSmithKline
Collaborators: ENGOT, GOG, APGOT
Conditions
(from sponsor)		 Neoplasms, Endometrial
Related terms Endometrial Neoplasms
Enrollment 610 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov